Viatris SG&A Expenses 2010-2024 | VTRS
Viatris annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Viatris sg&a expenses for the quarter ending December 31, 2024 were $1.047B, a 34.82% decline year-over-year.
- Viatris sg&a expenses for the twelve months ending December 31, 2024 were $4.426B, a 4.83% decline year-over-year.
- Viatris annual sg&a expenses for 2024 were $4.426B, a 4.83% decline from 2023.
- Viatris annual sg&a expenses for 2023 were $4.65B, a 11.27% increase from 2022.
- Viatris annual sg&a expenses for 2022 were $4.179B, a 7.73% decline from 2021.
| Viatris Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $4,426 |
| 2023 | $4,650 |
| 2022 | $4,179 |
| 2021 | $4,529 |
| 2020 | $3,345 |
| 2019 | $2,564 |
| 2018 | $2,441 |
| 2017 | $2,576 |
| 2016 | $2,499 |
| 2015 | $2,181 |
| 2014 | $1,626 |
| 2013 | $1,409 |
| 2012 | $1,392 |
| 2011 | $1,215 |
| 2010 | $1,087 |
| 2009 | $1,050 |
| Viatris Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024-12-31 | $1,047 |
| 2024-09-30 | $1,003 |
| 2024-06-30 | $1,358 |
| 2024-03-31 | $1,018 |
| 2023-12-31 | $1,606 |
| 2023-09-30 | $1,054 |
| 2023-06-30 | $1,032 |
| 2023-03-31 | $959 |
| 2022-12-31 | $1,265 |
| 2022-09-30 | $1,017 |
| 2022-06-30 | $981 |
| 2022-03-31 | $915 |
| 2021-12-31 | $1,083 |
| 2021-09-30 | $1,055 |
| 2021-06-30 | $1,205 |
| 2021-03-31 | $1,187 |
| 2020-12-31 | $1,361 |
| 2020-09-30 | $658 |
| 2020-06-30 | $719 |
| 2020-03-31 | $605 |
| 2019-12-31 | $654 |
| 2019-09-30 | $633 |
| 2019-06-30 | $669 |
| 2019-03-31 | $608 |
| 2018-12-31 | $633 |
| 2018-09-30 | $577 |
| 2018-06-30 | $623 |
| 2018-03-31 | $608 |
| 2017-12-31 | $660 |
| 2017-09-30 | $664 |
| 2017-06-30 | $621 |
| 2017-03-31 | $631 |
| 2016-12-31 | $711 |
| 2016-09-30 | $657 |
| 2016-06-30 | $581 |
| 2016-03-31 | $549 |
| 2015-12-31 | $596 |
| 2015-09-30 | $537 |
| 2015-06-30 | $564 |
| 2015-03-31 | $483 |
| 2014-12-31 | $426 |
| 2014-09-30 | $418 |
| 2014-06-30 | $404 |
| 2014-03-31 | $378 |
| 2013-12-31 | $392 |
| 2013-09-30 | $350 |
| 2013-06-30 | $315 |
| 2013-03-31 | $351 |
| 2012-12-31 | $355 |
| 2012-09-30 | $342 |
| 2012-06-30 | $359 |
| 2012-03-31 | $337 |
| 2011-12-31 | $301 |
| 2011-09-30 | $319 |
| 2011-06-30 | $314 |
| 2011-03-31 | $280 |
| 2010-12-31 | $290 |
| 2010-09-30 | $272 |
| 2010-06-30 | $268 |
| 2010-03-31 | $256 |
| 2009-12-31 | $269 |
| 2009-09-30 | $260 |
| 2009-06-30 | $280 |
| 2009-03-31 | $242 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.258B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||